Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized …

B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang… - JAMA …, 2018 - jamanetwork.com
Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …
被引用次数：505 相关文章
[PDF] brotop.cn

[PDF][PDF] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer The ALTER 0303 Phase 3 …

B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang, Y Cheng… - zlyy.w.brotop.cn
OBJECTIVE To investigate the efficacy of anlotinib on overall survival of patients with
advanced NSCLC progressing after second-line or further treatment. DESIGN, SETTING …
[PDF] lnskaxh.com

[PDF][PDF] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer The ALTER 0303 Phase 3 …

B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang, Y Cheng… - lnskaxh.com
OBJECTIVE To investigate the efficacy of anlotinib on overall survival of patients with
advanced NSCLC progressing after second-line or further treatment. DESIGN, SETTING …

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 …

B Han, K Li, Q Wang, L Zhang, J Shi… - JAMA …, 2018 - pubmed.ncbi.nlm.nih.gov
Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …
[HTML] nih.gov

[HTML][HTML] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 …

B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang… - JAMA …, 2018 - ncbi.nlm.nih.gov
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With
Advanced Non–Small Cell Lung Cancer - PMC Back to Top Skip to main content NIH NLM …
[PDF] tmucih.com

[PDF][PDF] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer The ALTER 0303 Phase 3 …

B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang, Y Cheng… - tmucih.com
OBJECTIVE To investigate the efficacy of anlotinib on overall survival of patients with
advanced NSCLC progressing after second-line or further treatment. DESIGN, SETTING …
[PDF] researchgate.net

[PDF][PDF] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer The ALTER 0303 Phase 3 …

B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang, Y Cheng… - JAMA, 2018 - researchgate.net
OBJECTIVE To investigate the efficacy of anlotinib on overall survival of patients with
advanced NSCLC progressing after second-line or further treatment. DESIGN, SETTING …
[PDF] tjmuch.com

[PDF][PDF] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer The ALTER 0303 Phase 3 …

B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang, Y Cheng… - tjmuch.com
OBJECTIVE To investigate the efficacy of anlotinib on overall survival of patients with
advanced NSCLC progressing after second-line or further treatment. DESIGN, SETTING …

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 …

B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang… - JAMA …, 2018 - europepmc.org
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With
Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial …
[PDF] tmucih.com

[PDF][PDF] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer The ALTER 0303 Phase 3 …

B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang, Y Cheng… - tmucih.com
OBJECTIVE To investigate the efficacy of anlotinib on overall survival of patients with
advanced NSCLC progressing after second-line or further treatment. DESIGN, SETTING …